Thomas J. Matthews

Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV‐1_Mngp120, HIV‐1_SF2Recombinant gp120, or Both Vaccines in Seronegative Adults

Mary Lou Clements‐Mann, Kent J. Weinhold, Thomas J. Matthews et al. · The Journal of Infectious Diseases · 1998 · 190 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

ANTIVIRAL ACTIVITY IN MILK OF POSSIBLE CLINICAL IMPORTANCE

Thomas J. Matthews · The Lancet · 1976 · 102 citations

Agriculture, Immunology, Maternal Health +9

Antibodies from Human Immunodeficiency Virus-Infected Individuals Bind to a Short Amino Acid Sequence that Elicits Neutralizing Antibodies in Animals

William R. Kenealy, Thomas J. Matthews, M C Ganfield et al. · AIDS Research and Human Retroviruses · 1989 · 60 citations

Pharmacy, Immunology, Infectious Diseases +12

Safety and Immunogenicity of a Live Recombinant Canarypox Virus Expressing HIV Type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) Followed by a p24E-V3 MN Synthetic Peptide (CLTB-36) Administered in Healthy Volunteers at Low Risk for HIV Infection

Dominique Salmon‐Céron, Jean‐Louis Excler, Laurent Finkielsztejn et al. · AIDS Research and Human Retroviruses · 1999 · 58 citations

Life Sciences, Immunology, Infectious Diseases +17

Human immunodeficiency virus‐1 disease progression in hemophiliacs

Paul Becherer, M. Lynn Smiley, Thomas J. Matthews et al. · American Journal of Hematology · 1990 · 37 citations

Life Sciences, Immunology, Infectious Diseases +10